Carlsbad startup Pardes Biosciences, which has begun clinical trials for an experimental pill to treat COVID-19, has raised $199 million through a special purpose acquisition company, or SPAC.
Founded in February 2020 specifically to fight the pandemic, the company is pursuing a protease inhibitor antiviral compound called PBI-0451. It aims to offer initial treatment for people with the virus — potentially sidetracking serious illness and keeping them out of overwhelmed hospitals.
“The world needs some sort of pill that you can take at home,” Heidi Henson, Pardes Biosciences’ chief financial officer, said in an interview. “I think the future is moving toward a telehealth
Read Full Article at www.latimes.com